Evidence map›Paper›PMID 39551851›Full record

Trial reportChinese journal of integrative medicine2025

Efficacy and Safety of Yangxue Qingnao Pills Combined with Amlodipine in Treatment of Hypertensive Patients with Blood Deficiency and Gan-Yang Hyperactivity: A Multicenter, Randomized Controlled Trial.

Fan Wang, Hai-Qing Gao, Zhe Lyu, Xiao-Ming Wang, Hui Han, Yong-Xia Wang, Feng Lu, Bo Dong, Jun Pu, Feng Liu and 10 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Chinese journal of integrative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Fan WangDepartment of the Cardiology, Chinese PLA General Hospital, Beijing, 100853, China.
Hai-Qing GaoDepartment of Geriatric, Qilu Hospital of Shandong University, Jinan, 250012, China.
Zhe LyuDepartment of Encephalopathy, Zhumadian Traditional Chinese Medicine Hospital, Zhumadian, Henan Province, 463000, China.
Xiao-Ming WangDepartment of Geriatric, Xijing Hospital of Air Force Medical University, Xi'an, 710032, China.
Hui HanDepartment of Geriatric, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Yong-Xia WangDepartment of the Cardiology, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China.
Feng LuDepartment of the Cardiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.
Bo DongDepartment of the Cardiology, the Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, 110034, China.
Jun PuDepartment of the Cardiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, 637000, China.
Feng LiuDepartment of Geriatric, Guangzhou First People's Hospital, Guangzhou, 510180, China.
Xiu-Guang ZuDepartment of the Cardiology, the Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Hong-Bin LiuDepartment of the Cardiology, Chinese PLA General Hospital, Beijing, 100853, China.
Li YangDepartment of Geriatric, Yan'an Hospital of Kunming City, Kunming, 650051, China.
Shao-Ying ZhangGeneral Department, the Central Hospital of Wuhan, Wuhan, 430014, China.
Yong-Mei YanDepartment of Encephalopathy, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shanxi Province, 712000, China.
Xiao-Li WangDepartment of Geriatric, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, 121001, China.
Jin-Han ChenHealcare Department for Cadres, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian Province, 361003, China.
Min LiuSpecialized Department of Hypertension, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Yun-Mei YangDepartment of Geriatric, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310003, China.
Xiao-Ying LiDepartment of the Cardiology, Chinese PLA General Hospital, Beijing, 100853, China. xyli301@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the clinical efficacy and safety of Yangxue Qingnao Pills (YXQNP) combined with amlodipine in treating patients with grade 1 hypertension.

methodsThis is a multicenter, randomized, double-blind, and placebo-controlled study. Adult patients with grade 1 hypertension of blood deficiency and Gan (Liver)-yang hyperactivity syndrome were randomly divided into the treatment or the control groups at a 1:1 ratio. The treatment group received YXQNP and amlodipine besylate, while the control group received YXQNP's placebo and amlodipine besylate. The treatment duration lasted for 180 days. Outcomes assessed included changes in blood pressure, Chinese medicine (CM) syndrome scores, symptoms and target organ functions before and after treatment in both groups. Additionally, adverse events, such as nausea, vomiting, rash, itching, and diarrhea, were recorded in both groups.

resultsA total of 662 subjects were enrolled, of whom 608 (91.8%) completed the trial (306 in the treatment and 302 in the control groups). After 180 days of treatment, the standard deviations and coefficients of variation of systolic and diastolic blood pressure levels were lower in the treatment group compared with the control group. The improvement rates of dizziness, headache, insomnia, and waist soreness were significantly higher in the treatment group compared with the control group (P<0.05). After 30 days of treatment, the overall therapeutic effects on CM clinical syndromes were significantly increased in the treatment group as compared with the control group (P<0.05). After 180 days of treatment, brachial-ankle pulse wave velocity, ankle brachial index and albumin-to-creatinine ratio were improved in both groups, with no statistically significant differences (P>0.05). No serious treatment-related adverse events occurred during the study period.

conclusionsCombination therapy of YXQNP with amlodipine significantly improved symptoms such as dizziness and headache, reduced blood pressure variability, and showed a trend toward lowering urinary microalbumin in hypertensive patients. These findings suggest that this regimen has good clinical efficacy and safety. (Registration No. ChiCTR1900022470).

Indexed as

AmlodipineAntihypertensive AgentsDrugs, Chinese HerbalHypertensionAdultAgedBlood PressureDouble-Blind MethodDrug Therapy, CombinationFemaleHumansMaleMiddle AgedTreatment OutcomeAmlodipineAntihypertensive AgentsDrugs, Chinese Herbalblood pressure variabilityChinese medicine syndrome scorehypertension with blood deficiency and Gan-yang hyperactivityYangxue Qingnao Pills

Identifiers

PMID39551851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.